Earth Capital

Earth Capital is a London-based sustainable investor working at the intersection of private equity and venture capital, backing technologies that promote planetary health and biological resilience. The platform applies an environmental and sustainability lens across its strategy, with healthcare-relevant exposure concentrated in deep tech and biotechnology applications that touch ecosystem health, food systems, and biological infrastructure. The firm is not positioned as a traditional therapeutics investor or as an AI specialist, and its mandate explicitly weights sustainability impact alongside financial return. Limited public information is available about specific named partners managing health-adjacent biotech investments.

Earth Capital concentrates on Series A and Series B stages, with checks in the $1M to $5M range that suit growth-stage companies with operating businesses and scaling capital needs. Geographic focus spans the United Kingdom and broader Europe from a London base, with selective consideration of global opportunities that fit the sustainability thesis. The firm typically co-invests with climate and impact-aligned funds rather than mainstream healthcare specialists.

For founders, Earth Capital is best understood as an impact-aligned partner for biotech and deep tech companies whose work supports planetary or biological systems, including agricultural biotech, environmental health, and bio-infrastructure. Founders should expect material diligence on environmental, social, and governance metrics in addition to standard commercial criteria. Companies focused purely on human therapeutics or clinical care delivery will likely find a better fit with sector-specialist healthcare investors. For founders working on biology with planetary impact, Earth Capital provides aligned capital and a clear sustainability narrative.